Jupiter Wellness initiates JW-100 study in the treatment of herpes labialis

Jupiter Wellness announced it has initiated an exploratory clinical study in the treatment of herpes labialis for its prescription topical cream candidate JW-100. This trial may be the first, to Jupiter's knowledge, to explore and ultimately show the efficacy of a combination CBD-aspartame product in the treatment of herpes labialis. JW-100's dual mechanism of action and relief combines CBD's potential ability to induce apoptosis in epithelial cells infected with Kaposi sarcoma-associated herpes virus, with aspartame's analgesic and anti-inflammatory properties. The double-blind, placebo-controlled study will recruit 40 patients diagnosed with recurrent herpes labialis infection, or HSV, who had their initial infection more than one year prior. Patients will be enrolled through clinical sites in Europe and Asia. The primary endpoint of the study is the duration of the herpes labialis episode.